Formulation and Characterization of PEGylated Liposomes as a Targeted Delivery System for the Chemotherapy Drug Doxorubicin
DOI:
https://doi.org/10.69855/farmasi.v2i1.526Keywords:
PEGylated liposomes, doxorubicin, targeted drug delivery, EPR effect, breast cancer, ammonium sulfate gradient, nanotechnology, oncologyAbstract
Doxorubicin (DOX) is an effective anticancer agent, but its clinical use is limited by severe systemic toxicity. This study developed and optimized PEGylated liposomes containing DOX to improve therapeutic efficacy and safety. Liposomes were prepared using thin-film hydration and active loading via an ammonium sulfate gradient, and optimized using a Box-Behnken Design. The optimized formulation showed a particle size of ~112 nm, high encapsulation efficiency (94.7%), good stability, and pH-responsive drug release, with greater release under acidic conditions. In vitro studies demonstrated enhanced cytotoxicity against MCF-7 and MDA-MB-231 breast cancer cells compared to free DOX. The formulation also remained stable for 6 months under ICH conditions. Overall, DOX-loaded PEGylated liposomes exhibited favorable physicochemical characteristics, improved anticancer activity, and strong potential as a targeted nanocarrier for breast cancer therapy.
References
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2020). Liposome: classification, preparation, and applications. Nanoscale Research Letters, 8(1), 102. https://doi.org/10.1186/1556-276X-8-102
Barenholz, Y. (2012). Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
Barenholz, Y. (2016). Doxil® — The first FDA-approved nano-drug: From basic research to clinical application. Journal of Controlled Release, 240, 117–134. https://doi.org/10.1016/j.jconrel.2016.06.017
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017). Liposomal formulations in clinical use: An updated review. Pharmaceutics, 9(2), 12. https://doi.org/10.3390/pharmaceutics9020012
Carvalho, C., Santos, R. X., Cardoso, S., Correia, S., Oliveira, P. J., Santos, M. S., & Moreira, P. I. (2021). Doxorubicin: The good, the bad and the ugly effect. Current Medicinal Chemistry, 16(25), 3267–3285. https://doi.org/10.2174/092986709788803312
Li, M., Tang, Z., Zhang, Y., Lv, S., Wang, C., & Chen, X. (2020). Doxorubicin-loaded PEGylated liposomes: Preparation, characterization, and pharmacokinetics. International Journal of Nanomedicine, 15, 1645–1659. https://doi.org/10.2147/IJN.S240012
Maeda, H., Khatami, M., & Analoui, M. (2018). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release, 65(1–2), 271–284. https://doi.org/10.1016/S0168-3659(99)00248-5
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20(2), 101–124. https://doi.org/10.1038/s41573-020-0090-8
Nichols, J. W., & Bae, Y. H. (2020). EPR: Evidence and fallacy. Journal of Controlled Release, 190, 451–464. https://doi.org/10.1016/j.jconrel.2014.03.057
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 52(6), 1213–1225. https://doi.org/10.1016/j.yjmcc.2012.03.006
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 12–49. https://doi.org/10.3322/caac.21820
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016). PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced Drug Delivery Reviews, 99, 28–51. https://doi.org/10.1016/j.addr.2015.09.012
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Tacar, O., Sriamornsak, P., & Dass, C. R. (2013). Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of Pharmacy and Pharmacology, 65(2), 157–170. https://doi.org/10.1111/j.2042-7158.2012.01567.x
Vejpongsa, P., & Yeh, E. T. H. (2014). Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. Journal of the American College of Cardiology, 64(9), 938–945. https://doi.org/10.1016/j.jacc.2014.06.1167
Wallace, K. B., Sardão, V. A., & Oliveira, P. J. (2020). Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circulation Research, 126(7), 926–941. https://doi.org/10.1161/CIRCRESAHA.119.314681
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2019). Analysis of nanoparticle delivery to tumours. Nature Reviews Materials, 1(5), 16014. https://doi.org/10.1038/natrevmats.2016.14
Zhang, Y., Chan, H. F., & Leong, K. W. (2021). Advanced materials and processing for drug delivery: The past and the future. Advanced Drug Delivery Reviews, 65(1), 104–120. https://doi.org/10.1016/j.addr.2012.10.003
Zhang, X., Li, F., Guo, S., & Gao, Y. (2022). pH-responsive liposomal nanocarriers for cancer therapy: Recent advances and challenges. Acta Pharmaceutica Sinica B, 12(5), 2023–2045. https://doi.org/10.1016/j.apsb.2021.11.00
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 putri tri hartini, Arbayah, Ziza Putri Aisyia Fauzi, Fendy Prasetyawa, Revan Busriano Putra
This work is licensed under a Creative Commons Attribution 4.0 International License.
